From a clinical perspective, PTM-centered interventions—ranging from small-molecule inhibitors to glyco-engineered antibodies and next-generation biologics—offer promising opportunities to overcome resistance to PD-1/PD-L1 blockade and to deliver durable, personalized cancer immunotherapies. The gene discussed is CD274; the disease is cancer.